Boehringer Ingelheim and Zealand Pharma's obesity drug candidate achieves 15% weight reduction in phase II
Boehringer Ingelheim has told MedWatch it plans to enter phase III study talks with authorities this summer.
by christopher due karlsson, translated by daniel pedersen
On Wednesday, Danish biotech company Zealand Pharma and its German partner, Boehringer Ingelheim, presented results from a phase II study of obesity treatment candidate BI 456906.
Already a subscriber?Log in here
Read the whole article
Get access for 14 days for free. No credit card is needed, and you will not be automatically signed up for a paid subscription after the free trial.
